Method for predicting risk of cognitive deterioration
A risk, level technology, applied in the field of prognosis and treatment, genetic vulnerability, indicators of brain iron levels, can solve problems such as not
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0160] Example 1: Ferritin levels in cerebrospinal fluid predict Alzheimer's disease outcome and are regulated by APOE
[0161] Ferritin is the body's major iron storage protein; the effect of brain iron status on longitudinal outcomes was investigated in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort by using cerebrospinal fluid (CSF) levels of ferritin as an indicator.
[0162] This example shows the association of baseline CSF-ferritin data with 7-year biomarker, cognitive, anatomical and diagnostic outcomes in the Alzheimer's Disease Neuroimaging Initiative (ADNI) prospective clinical cohort. It shows that CSF ferritin levels are comparable to the more established AD CSF biomarkers tau / Ab in predicting various outcomes in AD. 1–42 Ratio and Apolipoprotein E (ApoE) level comparison serve a similar purpose.
[0163] (i) method
[0164] ADNI description. Data were downloaded from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc....
Embodiment 2
[0207] Example 2: Cerebrospinal ferritin determines the risk of cognitive decline in preclinical APOE-ε4 carriers
[0208] The ε4 allele of apolipoprotein E (ApoE) confers the greatest risk of Alzheimer's disease (AD) and increases cerebrospinal fluid (CSF) ferritin by approximately 20% due to ε4 carriage (Ayton S et al (2015)) , recent data implicate brain iron accumulation as a risk vector. CSF ferritin levels predict longitudinal cognitive performance and risk of transition to AD in subjects with mild cognitive impairment (MCI). This example shows that CSF ferritin correlates with established AD risk variables APOE-ε4, CSF tau / Aβ in predicting 7-year cognitive decline in normal population 1-42 Binds to ApoE.
[0209] (i) method
[0210] This example uses data obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu; July 15, 2014).
[0211] Aβ 1-42 Baseline CSF levels of , tau (Luminex), ApoE, ferritin (Myriad Rules Based Medicin...
Embodiment 3
[0222] Example 3: Assessing a Patient's Risk of Cognitive Degeneration
[0223] In practicing the methods of the invention, it is contemplated that the patient's level of cognitive ability will be assessed. This level will provide the basis for determining whether they will degrade over time. The patient may have shown signs of cognitive impairment following the assessment.
[0224] CSF samples can be obtained and CSF ferritin levels determined by methods such as immunoassays and the like. This sample can then be compared to predetermined samples from CN patients processed in the same manner.
[0225] Differences in CSF ferritin levels between the patients and CN patients will be determined. Based on the magnitude of the difference, the degree of cognitive decline can be determined. If the difference is large and the patient's CSF ferritin level is high relative to the CN patient level, the assessed patient would show a higher risk of cognitive decline. If the difference ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com